ASX Announcement

30 July 2026

Quarterly Activities & Cash Flow Report
Quarter ended 30 June 2026

OncoSil Medical Delivers Strong Commercial Growth and Strategic Execution in Q4 FY26

Key highlights

- Strong sales growth reflects increasing commercial adoption
- Positive TRIPP-FFX results and ESMO GI presentation mark key growth milestones
- FDA HDE application advances to final review stage
- TGA approval opens Australian commercial opportunity
- Real-world clinical data presented at ESGE and ASCO supports OncoSil™ adoption
- Peer-reviewed study validates localised mechanism of action for the OncoSil™ device
- Italian ethics approval streamlines commercial rollout
- Cash and cash equivalents of $6.5 million as at 30 June 2026

Sydney, Australia – 30 July 2026: OncoSil Medical Limited (ASX: OSL) ("OncoSil Medical" or "the Company"), a medical device company focused on localised treatments for patients with unresectable locally advanced pancreatic cancer (LAPC), is pleased to announce its Appendix 4C cash flow report for the quarter ended 30 June 2026 (Q4 FY26), along with the following financial and operational update.

***OncoSil Medical CEO & Managing Director Nigel Lange, said**:*
"This quarter represents one of the most significant periods in OncoSil Medical's history, with major clinical, regulatory and scientific achievements that continue to strengthen our long-term growth outlook.

During the quarter, the Company's centre footprint growth was affected by a delay to the commencement of the G-BA clinical trial in Germany, now anticipated to begin later in calendar year 2026, within FY27. Germany benefits from a central ethics approval process for the study, with individual site activations expected to occur on a staggered basis. OncoSil continues to expand its treatment centre network globally and expects to approach approximately 50 active centres across all markets by the end of calendar year 2026.

During the quarter, we achieved a number of transformational milestones that significantly strengthened our competitive position. The positive TRIPP-FFX study results, including the successful achievement of both co-primary endpoints, provide a clear pathway to expanding the OncoSil™ label to include FOLFIRINOX, the current standard-of-care chemotherapy regimen for patients with unresectable locally advanced pancreatic cancer. In addition, we advanced our U.S. Humanitarian Device Exemption application to the final stage of FDA review,

received TGA approval to commercialise the OncoSil™ device in Australia, and further streamlined commercial access in Italy through important ethics and procurement approvals.

Our growing body of clinical evidence also received significant international recognition during the quarter through presentations at ESMO GI, ASCO and ESGE, together with new peer-reviewed publications supporting the safety, efficacy and targeted mechanism of action of the OncoSil™ device. These achievements continue to strengthen physician confidence, support broader commercial adoption, and reinforce our conviction that the OncoSil™ device is well positioned to become an increasingly important treatment option for patients with pancreatic cancer.

With multiple regulatory, clinical and commercial catalysts ahead, we believe OncoSil Medical is exceptionally well positioned to continue delivering sustainable growth and creating long-term value for shareholders through FY27."

Strong sales growth reflects increasing commercial adoption

OncoSil Medical delivered another year of strong commercial growth, with unit sales increasing 53% and revenue growing 44% in FY26 compared with FY25. The growth reflects increasing adoption of the OncoSil™ device across key European markets, driven by expanding utilisation at existing treatment centres, the addition of new commercial sites, and growing physician confidence supported by the Company's expanding clinical evidence and regulatory achievements.

For investors, the strong growth in both unit sales and revenue demonstrates that OncoSil Medical is successfully converting its clinical and regulatory progress into commercial performance. With multiple growth catalysts now in place, including expanded market access, regulatory approvals, strengthened clinical evidence, improved reimbursement and procurement pathways, and increasing physician adoption—the Company is well positioned to build on this momentum and continue delivering sustainable revenue growth across existing and new markets.

Positive TRIPP-FFX results and ESMO GI presentation mark key growth milestones

OncoSil Medical achieved a significant clinical milestone during the quarter with the TRIPP-FFX trial meeting both co-primary endpoints of safety/tolerability and 16-week local disease control in patients with unresectable locally advanced pancreatic cancer (LAPC). The study demonstrated that adding OncoSil™ to standard-of-care FOLFIRINOX chemotherapy delivered an 82.2% local disease control rate and median overall survival of 18.3 months, while maintaining a manageable safety profile. These positive results support the Company's planned regulatory submission to expand the European and UK product label to include FOLFIRINOX, aligning OncoSil™ with current treatment practice and potentially broadening its commercial opportunity.

For investors, the TRIPP-FFX results represent a major value inflection point. As the first prospective randomised study evaluating OncoSil™ alongside FOLFIRINOX, the data substantially strengthens the clinical

evidence supporting adoption of the technology. Subject to regulatory approval, label expansion is expected to simplify physician referral pathways, increase patient eligibility and support broader commercial uptake across key European markets, reinforcing the Company's growth strategy.

Further validating the significance of these results, the TRIPP-FFX study was selected for a Rapid Oral Presentation at ESMO GI 2026, one of the world's leading gastrointestinal oncology congresses. The study was presented on 4 July 2026 by Professor Michele Milella, Professor of Medical Oncology at the University of Verona, Italy, and Principal Investigator of the TRIPP-FFX trial. The presentation provides a high-profile platform to showcase the clinical data to leading gastrointestinal cancer specialists, researchers and potential strategic partners. This prestigious selection reinforces the scientific significance of the study, enhances OncoSil Medical's global clinical profile, and supports the Company's ongoing regulatory and commercial objectives, representing another important catalyst for long-term shareholder value.

FDA HDE application advances to final review stage

OncoSil Medical achieved another significant regulatory milestone during the quarter, with the U.S. Food and Drug Administration (FDA) confirming that all outstanding questions relating to the Company's Humanitarian Device Exemption (HDE) application for the treatment of distal cholangiocarcinoma (dCCA) had been satisfactorily addressed. The application advanced to the final stage of FDA review, with only final device labelling and any post-market study updates required before a potential approval decision. The Company subsequently submitted its final HDE package to the FDA on 2 July 2026, commencing the FDA's targeted 45-day review period and bringing OncoSil™ to the final step before potential U.S. approval.

For investors, this represents a major regulatory inflection point and the most advanced stage reached in OncoSil Medical's U.S. regulatory program. HDE approval would enable the Company to commercialise OncoSil™ in the United States for the treatment of dCCA, a rare cancer with limited treatment options and significant unmet clinical need. Successful entry into the U.S. market would provide an important new commercial opportunity, diversify future revenue streams, and further validate the Company's regulatory and clinical strategy.

TGA approval opens Australian commercial opportunity

The Company secured a key domestic regulatory approval during the quarter, receiving Therapeutic Goods Administration (TGA) approval for the OncoSil™ device for the treatment of unresectable LAPC in addition to gemcitabine-based chemotherapy. The approval, which includes listing on the Australian Register of Therapeutic Goods (ARTG), enables commercialisation of OncoSil™ in Australia and makes it the first and only TGA-approved Class III medical device targeting tumours directly within the pancreas. This milestone validates the Company's clinical and regulatory program while providing Australian clinicians and patients with access to a novel treatment option for a disease with significant unmet medical need.

In Australia, an estimated 30% of the approximately 4,353 patients diagnosed with pancreatic cancer each year present with locally advanced pancreatic cancer (LAPC)[1], representing an addressable population of

approximately 1,300 patients per annum once fully reimbursed. TGA approval establishes a new commercial market in Australia and validates the Company's regulatory strategy in this jurisdiction. The approval is expected to support broader physician adoption and strengthen the growing body of clinical evidence supporting OncoSil™. The expected completion of the Company's new manufacturing facility in Macquarie Park, Sydney, developed in partnership with Cyclotek, will also strengthen domestic production capability and global supply chain capacity as commercial operations continue to scale.

Real-world clinical data presented at ESGE and ASCO supports OncoSil™ adoption

OncoSil Medical expanded its clinical evidence base during the quarter through presentations at two of the world's leading international medical congresses. Interim results from the OSPREY Registry were presented by Dr Enrique Vázquez-Sequeiros of University Hospital Ramón y Cajal, Madrid, Spain, at ESGE Days 2026 (European Society of Gastrointestinal Endoscopy Days), demonstrating a strong safety profile, 91.4% local disease control in first-line patients, median overall survival of 20.6–22.0 months, and successful downstaging to surgery in selected patients treated in routine clinical practice across Europe. The Spanish multi-centre clinical experience was also presented by Dr Carmen Guillen-Ponce of Hospital Universitario Ramón y Cajal, Madrid, Spain, at the ASCO Annual Meeting 2026 (American Society of Clinical Oncology Annual Meeting) on 30 May 2026, highlighting favourable safety outcomes, encouraging survival and the potential for conversion to curative surgery in patients initially considered unresectable.

These presentations provide important independent validation of OncoSil™ in real-world clinical practice and reinforce the growing body of evidence supporting broader physician adoption. The OSPREY Registry demonstrated outcomes that compare favourably with historical benchmarks for chemotherapy alone, while the Spanish experience further highlighted the potential for OncoSil™ to increase surgical eligibility in patients with unresectable disease. Supporting these findings, a peer-reviewed case report published in Cureus described a patient who remained disease-free 50 months after diagnosis following treatment with OncoSil™ and chemotherapy, demonstrating the long-term clinical potential of the therapy. Together, these independent datasets strengthen the Company's clinical credibility, support future regulatory and commercial initiatives, and reinforce confidence in the long-term adoption of the OncoSil™ device.

Peer-reviewed study validates localised mechanism of action of OncoSil™

OncoSil Medical further strengthened the scientific evidence supporting its technology during the quarter with the publication of new peer-reviewed histopathological findings in Pathology International. The study, conducted by investigators from the Royal Adelaide Hospital and the University of Adelaide, provides the first pathological evidence demonstrating that implanted OncoSil™ microparticles remain confined within tumour tissue following implantation in patients with unresectable locally advanced pancreatic cancer (LAPC). The findings support the device's highly localised mechanism of action, with no evidence of microparticle migration to surrounding healthy tissue or organs, further enhancing its targeted therapeutic approach. Researchers also concluded that the findings may help optimise future dosing and implantation strategies, supporting continued product development and enhancing confidence in the Company's clinical and regulatory strategy.

Italian ethics approval streamlines commercial rollout

OncoSil Medical strengthened its commercial pathway in Italy during the quarter after receiving central ethics committee approval for the OSPRItaly post-market patient registry. The updated classification of the registry as an observational clinical registry enables participating hospitals to purchase the OncoSil™ device directly through a simplified negotiated procurement process, removing the need for separate ethics approvals at individual sites. The approval also formally recognises reimbursement for the standardised OncoSil™ implantation procedure within Italy's legal and regulatory framework, significantly reducing barriers to commercial adoption.

This represents an important commercial milestone in one of Europe's largest pancreatic cancer markets, with more than 16,000 new cases diagnosed annually. The streamlined procurement framework is expected to accelerate onboarding of new treatment centres, with the Company targeting an increase from four to eight authorised hospitals during 1H FY27, materially expanding its treatment network and supporting increased adoption of the OncoSil™ device. The approval also reflects growing real-world clinical acceptance, with OncoSil™ increasingly being incorporated into routine clinical practice across Italy.

Finance update

The Appendix 4C Quarterly Cash Flow report for the June 2026 quarter is attached to this announcement.

During the quarter ended 30 June 2026, OncoSil Medical continued to maintain disciplined financial management while advancing its commercialisation and clinical objectives.

The Company had $6.5 million in cash and cash equivalents as at 30 June 2026, decreasing by $2.8 million from $9.3 million at 31 March 2026.

The Company received customer receipts of $0.4 million during the quarter, bringing total customer receipts for the financial year to $2.1 million, an increase of 179% compared with the prior corresponding period.

Research and development payments decreased by $0.2 million from the prior quarter to $0.8 million, primarily due to the close-out phase of the TRIPP-FFX and PANCOSIL trials. The Company currently expects research and development cash outflows to remain at a similar level over the next quarter as trial activities are completed; however, following this period, outflows are expected to decline from the second quarter of FY27.

The Company continues to carefully manage its cost base while prioritising investment in:

- Sales growth in key existing markets to include Spain, Germany, Italy, Greece and Israel
- Regulatory approvals related to label expansion for additional chemotherapy and percutaneous application
- Completion of a purpose-built manufacturing facility to increase product gross margins and scale
- Commercial expansion in key territories

Management remains focused on aligning expenditure with strategic milestones and revenue generation opportunities.

Pursuant to Listing Rule 4.7C.3 and as disclosed in Item 6.1 of the attached Appendix 4C, $125,118 was paid in respect of remuneration of director fees in the normal course of business at commercial rates, excluding reimbursements of out-of-pocket expenses.

Milestones expected in FY27

1H FY27	2H FY27
• G-BA funded study commencement • FDA HDE approval for distal cholangiocarcinoma (dCCA) • EU regulatory submission – percutaneous label change (PANCOSIL) • EU regulatory submission – FOLFIRINOX label change (TRIPP-FFX) • Commercial sales from OncoSil Cyclotek manufacturing facility in Sydney*	• EU regulatory approval – percutaneous label change (PANCOSIL) • EU regulatory approval – FOLFIRINOX label change (TRIPP-FFX) • Launch of OncoSil™ device in Australia • Launch of OncoSil™ device in the United States*

* subject to approvals

Click **here** to view this announcement on Investor Hub

Authorisation & additional information

This announcement was authorised by the Board of Directors of OncoSil Medical Limited.

For further information, please contact:

Mr. Nigel Lange CEO & Managing Director E: nigel.lange@oncosil.com T: +49 160 96424981	**Mr. Tim Luscombe & Ms. Nova Taylor** Joint Company Secretaries E: tim.luscombe@bio101.com & nova.taylor@bio101.com T: +61 429 707 079 & +61 414 877 703

About OncoSil Medical

OncoSil Medical (ASX:OSL) is a global medical device company focused on Interventional Oncology. OncoSil Medical's mission is to improve the outcomes for people living with cancer by utilizing the selected and targeted intratumoural placement of Phosphorous-32 (^{32}P) Microparticles in addition to chemotherapy.

OncoSil Medical has developed OncoSil™ device for the treatment of unresectable locally advanced pancreatic cancer. Its targeted approach enables healthcare professionals to deliver a greater radiation dose directly into the tumour compared to external beam radiotherapy, while sparing surrounding critical organs.

Pancreatic cancer is the 12th most common cancer in men and the 11th most common cancer in women across the globe, with 500,000 new cases detected every year[1]. Since pancreatic cancer is generally diagnosed at a later stage, it has a poor prognosis for long-term survival.

OncoSil™ has received CE Marking approval, providing marketing authorisation in both the EU and the UK. OncoSil™ is designated as a breakthrough device in both Europe and the United States. It is currently approved for sale in 30+ countries including European Union, United Kingdom, Australia, Türkiye and Israel, with commercial treatments using the device already undertaken in Spain, Italy, Austria, Germany, Greece, Türkiye, Portugal, Israel and the UK.

To learn more, please visit: www.oncosil.com/

1. https://gco.iarc.fr/en

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity	
ONCOSIL MEDICAL LIMITED	
ABN	**Quarter ended ("current quarter")**
89 113 824 141	30 June 2026

Consolidated statement of cash flows		Current quarter $A'000	Year to date (12 months) $A'000
1.	**Cash flows from operating activities**		
1.1	Receipts from customers	391	2,115
1.2	Payments for		
	(a) research and development	(748)	(3,820)
	(b) product manufacturing and operating costs	(690)	(3,187)
	(c) advertising and marketing	(33)	(474)
	(d) leased assets	(16)	(72)
	(e) staff costs	(1,100)	(4,667)
	(f) administration and corporate costs	(571)	(2,626)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	56	140
1.5	Interest and other costs of finance paid	-	-
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	-	1,840
1.8	Other (provide details if material)	129	221
1.9	**Net cash from / (used in) operating activities**	**(2,582)**	**(10,529)**

2.	**Cash flows from investing activities**		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-

Consolidated statement of cash flows		Current quarter $A'000	Year to date (12 months) $A'000
	(f) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	**Net cash from / (used in) investing activities**	**-**	**-**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	13,459
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	3
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(237)	(1,546)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	**Net cash from / (used in) financing activities**	**(237)**	**11,916**

4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	9,293	5,110
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(2,582)	(10,529)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	-

Consolidated statement of cash flows		Current quarter $A'000	Year to date (12 months) $A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(237)	11,916
4.5	Effect of movement in exchange rates on cash held	2	(21)
4.6	**Cash and cash equivalents at end of period**	**6,476**	**6,476**

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter $A'000	Previous quarter $A'000
5.1	Bank balances	6,476	9,293
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**6,476**	**9,293**

6.	Payments to related parties of the entity and their associates	Current quarter $A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	125
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	-	-
7.4	**Total financing facilities**	-	-

7.5	**Unused financing facilities available at quarter end**	-

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

8.	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (item 1.9)	(2,582)
8.2	Cash and cash equivalents at quarter end (item 4.6)	6,476
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	6,476
8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)**	2.51

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer: n/a

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer: n/a

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: n/a

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: 30 July 2026

Authorised by: By the Board of Directors
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.